Sheets Smith Investment Management Boosts Stock Holdings in Veru Inc. $VERU

Sheets Smith Investment Management lifted its holdings in shares of Veru Inc. (NASDAQ:VERU) by 1,341.9% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 322,084 shares of the company’s stock after acquiring an additional 299,746 shares during the quarter. Sheets Smith Investment Management’s holdings in Veru were worth $1,224,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Atria Investments Inc lifted its position in shares of Veru by 11.5% during the second quarter. Atria Investments Inc now owns 282,281 shares of the company’s stock worth $164,000 after acquiring an additional 29,025 shares in the last quarter. Allworth Financial LP bought a new stake in shares of Veru during the 2nd quarter valued at $45,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Veru during the 2nd quarter valued at $90,000. Catalyst Funds Management Pty Ltd purchased a new stake in Veru during the 2nd quarter worth about $36,000. Finally, Sender Co & Partners Inc. boosted its stake in Veru by 82.8% in the 2nd quarter. Sender Co & Partners Inc. now owns 238,231 shares of the company’s stock worth $139,000 after purchasing an additional 107,911 shares during the period. 47.16% of the stock is currently owned by hedge funds and other institutional investors.

Veru Stock Performance

NASDAQ VERU opened at $2.26 on Friday. Veru Inc. has a 52-week low of $2.11 and a 52-week high of $14.20. The company has a fifty day moving average of $2.92 and a 200-day moving average of $4.11. The company has a market capitalization of $33.13 million, a P/E ratio of -1.03 and a beta of -1.01.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on VERU shares. Oppenheimer reaffirmed an “outperform” rating on shares of Veru in a report on Thursday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group initiated coverage on shares of Veru in a report on Thursday. They issued a “buy” rating and a $25.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.